Micro Interventional Devices has first-in-human success with MIA technology

167

Micro Interventional Devices has successfully completed the first clinical implantation of its proprietary MIA (minimally invasive annuloplasty) technology for minimally invasive mitral and tricuspid repair. 

The MIA implant is made from PolyCor anchors and MyoLast implantable elastomer. The MIA device is designed to reduce annular dimensions, and thus regurgitation, following deployment in the patient’s native annulus. The annular reduction is achieved without sutures or other intervention. This implantation represents the first clinical enrolment in the company’s STTAR clinical study. STTAR (the Study of Transcatheter Tricuspid Annular Repair) is a multicentre safety and performance study being conducted in Europe.

MIA was implanted during a minimally invasive tricuspid repair procedure concomitant with mitral valve repair. The procedure was performed by Kestutis Rucinskas, chief of Cardiac Surgery, and Audrius Aidietis, chief of Cardiology and Angiology, at the Vilnius University Hospital Santariskiu Clinic in Vilnius, Lithuania. There were no intraoperative complications or adverse events observed or reported.  Post-procedural patient recovery has been uneventful.

“On Tuesday, December 6th we successfully deployed nine MIA implants in our first patient’s tricuspid annulus during a minimally invasive tricuspid repair procedure,” Willard Hennemann, MID’s chief science officer, comments. “A significant reduction in valve area was observed post-procedure.  We look forward to enrolling additional patients in the STTAR study and to following these patients to assess the long term effect of MIA on valve insufficiency.”